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INTRODUCTION
Plasmodium vivax caused an estimated 13.8 million malaria 
cases in 2015, and was responsible for about a half of all ma-
laria cases outside Africa. In addition, the total number of ma-
laria deaths due to P. vivax was estimated to be between 1,400 
and 14,900 [1]. Understanding and characterizing the func-
tions of Plasmodium spp. proteins would facilitate develop-
ment of a vaccine against malaria. Although potential vaccine 
candidates have been identified using bioinformatics tools 
and the PlasmoDB database, and the number of candidates 
has been increasing, only 3 P. vivax candidate antigens for a 
malaria vaccine are at present in preliminary (phase I) clinical 
trials [2-4]. The proteins involved in invasion such as attach-
ment, junction formation, and internalization of host erythro-
cytes have been identified as important vaccine candidates lo-
cated on the surface or in the apical organelles of merozoites 
[5-7].
To date, 12 members of the s48/45 protein family (Pfs230, 
Pfs48/45, Pfs230p, Pfs47, P52, P36, Pf41, Pf38, Pf12, P12p, 
Pf92, and sequestrin) have been identified in P. falciparum par-
asites. These antigens are likely present on the surface of mero-
zoites (the asexual stage parasite that invades erythrocyte) and 
gametocytes (the sexual stage parasite in mosquitoes) [8,9]. 
One of the s48/45 protein family containing s48/45 domains, 
Pfs230, is expressed on the gametocyte surface, and specific 
antibodies against the s48/45 domain containing 6-cysteine 
(Cys) residues blocks oocyst production. In addition, the ab-
sence of Pfs230 showed significant inhibition of oocyst pro-
duction as well as mosquito infectivity [10-13]. Therefore, the 
Pfs48/45 antigens such as Pfs230 are potential vaccine candi-
dates for blocking transmission of malaria [14,15].
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Abstract: The discovery and understanding of antigenic proteins are essential for development of a vaccine against ma-
laria. In Plasmodium falciparum, Pf92 have been characterized as a merozoite surface protein, and this protein is ex-
pressed at the late schizont stage, but no study of Pv92, the orthologue of Pf92 in P. vivax, has been reported. Thus, the 
protein structure of Pv92 was analyzed, and the gene sequence was aligned with that of other Plasmodium spp. using 
bioinformatics tools. The recombinant Pv92 protein was expressed and purified using bacterial expression system and 
used for immunization of mice to gain the polyclonal antibody and for evaluation of antigenicity by protein array. Also, the 
antibody against Pv92 was used for subcellular analysis by immunofluorescence assay. The Pv92 protein has a signal 
peptide and a sexual stage s48/45 domain, and the cysteine residues at the N-terminal of Pv92 were completely con-
served. The N-terminal of Pv92 was successfully expressed as soluble form using a bacterial expression system. The an-
tibody raised against Pv92 recognized the parasites and completely merged with PvMSP1-19, indicating that Pv92 was 
localized on the merozoite surface. Evaluation of the human humoral immune response to Pv92 indicated moderate anti-
genicity, with 65% sensitivity and 95% specificity by protein array. Taken together, the merozoite surface localization and 
antigenicity of Pv92 implicate that it might be involved in attachment and invasion of a merozoite to a new host cell or im-
mune evasion during invasion process.
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In a previous report, Pf92 of the s48/45 protein family, 
which contains a single s48/45 domain, was expressed during 
merozoite stages, and contained a glycosylphosphatidylinosi-
tol-anchor (GPI-anchor) domain at the C-terminal. In addi-
tion, the central peptides of Pf92 showed high binding ability 
to erythrocytes, and a rabbit polyclonal anti-Pf92 antiserum 
strongly inhibited invasion of the P. falciparum parasite into 
erythrocytes. In addition, Pf92 has been confirmed as a mero-
zoite surface protein at the schizont stage [16,17]. However, 
homologues of Pf92 in other Plasmodium spp. remain unclear. 
Previous studies identified and characterized the localization 
and antigenicity of several 6-Cys proteins in P. vivax, such as 
Pv41 and Pv12, which are expressed on the surface and rhop-
try, respectively, of merozoites during the asexual cycle [18,19]. 
Antibodies against Pvs48/45 and Pvs47 expressed in gameto-
cytes of P. vivax reduced oocyst development, consistent with P. 
falciparum [20].
To date, few features of Pv92 are known; for instance, it be-
longs to the 6-Cys protein family and its expression level is 
low [21]. However, its localization and antigenicity have not 
been documented. Therefore, the Pv92 was expressed using an 
Escherichia coli protein expression system. The recombinant 
Pv92 protein was subjected to evaluation of antigenicity using 
a protein array and immunized into mice to obtain antiserum, 
which was used to confirm the subcellular localization of 
Pv92 in the late schizont.
MATERIALS AND METHODS
P. vivax sample collection and serum preparation
A total of 32 blood samples were collected from patients 
with confirmed vivax malaria via microscopy at local health 
centers and clinics in Gangwon Province, an endemic area in 
the Republic of Korea. A total of 23 blood samples were col-
lected from healthy donors who were confirmed vivax malaria 
negative via microscopy, and were used as controls. The Insti-
tutional Review Board at Kangwon National University Hospi-
tal approved this study. 
Bioinformatics analysis of Pv92
Gene sequence data and gene expression profiles of Pv92 as 
well as homologue genes were obtained from the PlasmoDB 
website (http://plasmodb.org; accession no. PVX_115165). 
Protein domains were further predicted using the Simple 
Modular Architecture Research Tool (SMART) (http://smart.
embl-heidelberg.de/) [22,23]. The gene sequence data of Pv92 
and those of other Plasmodium spp. were aligned using the 
DNASATR software (Lasergene, Madison, Wisconsin, USA).
Genomic DNA isolation
One of the above Korean P. vivax isolates was subjected to 
genomic DNA extraction using QIAamp DNA Blood Mini Kits 
(Qiagen, Hilden, Germany) according to the manufacturer’s 
instructions, and used for PCR amplification of the Pv92 gene. 
The purified genomic DNA was eluted in 200 µl of elution 
buffer and stored at -20˚C until use.
Cloning and protein expression of Pv92
The N-terminus of pv92 gene was amplified by PCR from 
genomic DNA and cloned using the pEXP5-NT/TOPO® TA Ex-
pression Kit (Thermo Fisher, Massachusetts, USA). For gene 
amplification, the following pair of primers was designed: 
Pv92-F (5ʹ-GTGTCCCTTGCAGGGGAGTT-3ʹ) and Pv92-R 
(5ʹ-TTAGCTAGGGGGCGCCCCTT-3ʹ). The sequences under-
lined are terminator codons. The PCR reaction system con-
tained 0.5 U Platinum Taq DNA Polymerase High Fidelity (In-
vitrogen, Carlsbad, California, USA), 0.2 µM of sense and anti-
sense primer, 50 ng of genomic DNA, 200 µM deoxyribonu-
cleotide triphosphates (dNTPs), and MgSO4 to a final concen-
tration of 2.0 mM. PCR amplification from genomic DNA was 
carried out under the following cycling conditions for 38 cy-
cles: 94˚C for 20 sec, 60˚C for 30 sec, 72˚C for 1 min, and a fi-
nal extension step at 72˚C for 10 min. The amplified gene was 
purified by PCR clean-up kit (Macherey-Nagel, Düren, Germa-
ny) according to the manufacturer’s instructions. The purified 
gene was incubated with pEXP5-NT/TOPO vector according to 
the manufacturer’s instructions, and then the cloned plasmid 
DNA was transformed into TOP10 competent cells by the 
heat-shock method. The DNA sequence was confirmed using 
the ABI PRISM 310 Genetic Analyzer and a Big Dye Terminator 
v1.1 Cycle sequencing kit (Applied Biosystems, Forster City, 
California, USA).
The clone was transformed into BL21(DE3) competent cells 
(Invitrogen) for protein expression. Production of the recom-
binant protein was induced by isopropyl-β- D-thiogalactopy-
ranoside (IPTG). The lysis of E. coli was carried out by lysis 
buffer (1 mg/ml lysozyme, 1 mM PMSF, 1mM DTT, 10 μM Le-
upeptine) and sonication, and the lysate centrifuged to gain 
the soluble fraction. The soluble fraction was incubated with 
Ni-NTA (Qiagen) for overnight and the recombinant protein 
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was eluted according to the manufacturer’s instructions. The 
purified recombinant protein was confirmed by SDS-PAGE 
and Western blot analysis.
Production of mouse immune sera
To generate antibodies, 20 µg of the purified protein Pv92 
was used for immunization of 3 female BALB/c mice (5-week-
old) (Daehan Biolink Co., Eumsung, Korea) with Freund’s 
complete adjuvant, followed by 20 µg with Freund’s incom-
plete adjuvant. Immunization was performed 3 times at 
2-week intervals. The animal experiment was approved by the 
Institutional Ethics Committee and we followed the Ethical 
Guidelines for Animal Experiments of Kangwon National 
University.
SDS-PAGE and Western blot analysis
The recombinant Pv92 protein was separated by 12% SDS-
PAGE under reducing conditions. The separated protein was 
transferred onto a 0.45 µm PVDF membrane (Millipore, Biller-
ica, Massachusetts, USA) in semi-dry transfer buffer (50 mM 
Tris, 190 mM glycine, 3.5 mM SDS, 20% methanol) at a con-
stant 400 mA for 40 min using a semi-dry blotting system 
(ATTO Corp., Tokyo, Japan). After blocking with 5% skim milk 
in PBS-T (0.5% v/v Tween-20 in 1×PBS), anti-histidine anti-
body (Qiagen), mouse immune serum, or mixed patient sera 
diluted 1:100 in PBS-T and secondary IRDye® goat anti-mouse 
(1:5,000 dilution) or IRDye® goat anti-human (1:20,000) (Li-
COR® Bioscience, Lincoln, Nebraska, USA) antibodies were 
used to detect recombinant protein. The results were visualized 
using the Odyssey infrared imaging system (Li-COR® Biosci-
ence) and analyzed using the Odyssey software (Li-COR® Bio-
science).
Indirect immunofluorescence assay (IFA)
Blood smears were prepared for IFA as described previously 
[19]. Slides smeared with schizont enriched blood were fixed 
with ice-cold acetone for 3 min, dried, and stored at -80˚C un-
til use. The frozen slides were thawed on silica gel blue (Samc-
hun Chemical, Pyeongtaek, Korea) and blocked with 5% BSA 
in PBS at 37˚C for 30 min. The slides were incubated with 
1:100 dilutions of primary antibodies (mouse anti-Pv92 and 
rabbit anti-PvMSP1-19) at 37˚C for 1 hr. The slides were then 
stained with Alexa Fluor 488-conjugated goat anti-rabbit IgG 
or Alexa Fluor 546-conjugated goat anti-mouse IgG secondary 
antibodies (Invitrogen) and the nuclei were stained with 
4’,6-diamidino-2-phenylindole (DAPI; Invitrogen) at 37˚C for 
30 min. The slides were mounted in ProLong Gold antifade 
reagent (Invitrogen) and visualized under oil immersion using 
a confocal laser scanning FV200 microscope (Olympus, To-
kyo, Japan). Images were captured using the FV10-ASW 3.0 
viewer software.
Assessment of antigenicity using protein array
The amine-coated slides were prepared as described previ-
ously [4]. A total of 32 or 20 serum samples from vivax pa-
tients or healthy persons, respectively, were used to evaluate 
the antigenicity of Pv92. One-hundred nanograms of Pv92 
protein were spotted on each well of a slide, and incubated for 
2 hr at 37˚C. After incubation, the wells were blocked with 5% 
BSA in PBS for 1 hr at 37˚C. Then, slides were incubated with 
human individual sera at a 1:10 dilution in PBS for 1 hr at 
37˚C and then with Alexa Fluor 546 goat anti-human IgG in 
PBS-T for 1 hr at 37˚C for visualization. The slides were 
scanned in a fluorescence scanner (Perkin Elmer, Boston, Mas-
sachusetts, USA) [24]. The mean fluorescence intensities (MFI) 
of spots were quantified by the fixed circle method using the 
ScanArray Express software version 4.0 (PerkinElmer). The 
positive cut-off MFI value was set as the MFI of serum samples 
from healthy individuals plus 2 SDs [25].
Statistical analysis
The data were analyzed with GraphPad Prism (GraphPad 
Software, San Diego, California, USA) and SigmaPlot (Systat 
Software Inc., San Jose, California, USA). Mann-Whitney U 
tests were used to determine the significance of differences be-
tween the means of the groups. Values of P<0.05 were consid-
ered to indicate statistical significance.
RESULTS
Bioinformatics analysis of Pv92 sequence
Pv92 gene sequence information encoded by PVX_115165 
on chromosome 11 retrieved from PlasmoDB revealed that the 
ORF of the Pv92 encodes an 888-amino-acid protein with a 
predicted molecular mass of 98.51 kDa. The Pv92 protein is 
encoded by a single exon gene, and consists of a signal peptide 
(amino acid [aa] 1-23), Pfs48/45 domain (aa 571-963), and 
GPI-anchor (aa 861-888) (Fig. 1A). Orthologues of Pv92 were 
found in 5 Plasmodium spp. including P. falciparum IT and 
3D7. To further characterize the Pv92 protein, the N-terminal 
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(aa 24-261) was aligned with orthologues in other Plasmodium 
spp. Five cysteine residues were completely conserved across 
the species examined (Fig. 1B).
Fig. 1. Schematic diagram and amino acid sequence alignment of Pv92 with homologues in other Plasmodium spp. (A) Schematic dia-
gram of Pv92. The Pv92 protein comprises 888 amino acids. Indicated are the signal peptide (aa 1-23), Pfs48/45 domain (aa 571-963), 
and GPI-anchor (aa 861-888). The N-terminal (aa 24-261) was constructed for protein expression. (B) Amino acid sequence alignment 
of N-terminal of Pv92 with 5 homologues in other Plasmodium spp. Cysteine residues are highlighted in yellow.
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Fig. 2. Recombinant Pv92 protein expression, purification, and Western-blot analysis. (A) Purified N-terminal of Pv92 protein. M, protein 
marker; arrow heads, purified Pv92; T, total fraction; S, soluble fraction; P, pellet fraction; Ft, flow-through; W, washing fraction; E, elution 
fraction. (B) Western-blot analysis of Pv92 using an anti-His antibody (lane 1), mouse immune serum (lane 2), pre-immune mouse serum 
(lane 3), pooled vivax patient sera (lane 4), and malaria-naïve human serum samples (lane 5). Arrowheads indicate Pv92.
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Expression and purification of Pv92, and western blotting 
analysis of immune serum against Pv92
The N-terminal of Pv92 was successfully expressed and puri-
fied under non-denaturing condition using an E. coli protein 
expression system, and the purity was confirmed by SDS-PAGE 
(Fig. 2A). Pv92 migrated as a single band of ~33 kDa under re-
ducing condition; the predicted size of Pv92 was slightly 
smaller, at ~28 kDa. Polyclonal antibodies against the protein 
were produced by immunizing mice with purified Pv92, and 
the serum was used to assess recombinant protein expression 
and localization at P. vivax schizonts. The serum against Pv92 
and P. vivax patient serum successfully recognized Pv92 in 
western blotting analysis (Fig. 2B).
Pv92 locates on the merozoite surface of parasites
To determine the localization of the Pv92 protein in mature 
schizonts, IFA was carried out using anti-Pv92 and -PvM-
SP1-19 sera. In parasites, Pv92 was localized to the surface of 
each merozoite (Fig. 3). As Pv92 was highly expressed only at 
the schizont stage throughout the 48 hr intraerythrocytic cycle, 
its localization was compared with the merozoite surface pro-
tein PvMSP1-19. The signal of Pv92 completely merged with 
that of MSP1-19, demonstrating that Pv92 is a merozoite sur-
face protein.
Humoral immune response to Pv92
To further evaluate the humoral immune response to Pv92, 
a protein array was used to screen the presence of antibodies 
in individual human sera. Antibody responses against Pv92 in 
serum samples from 32 patients infected with P. vivax and 20 
healthy individuals were determined. The responses of pa-
tients exposed to P. vivax were significantly higher than those 
of naïve subjects (Fig. 4, P<0.0001). The prevalence of anti-
Pv92 antibodies was also determined, indicating a sensitivity 
of 65% (21 positives of 32 vivax samples) and specificity of 
95% (19 negatives of 20 healthy samples) (Table 1).
DISCUSSION
A deeper understating of antigens involved in invasion is es-
sential for development of malaria vaccines. To identify prom-
ising P. vivax vaccine candidates, antigenic proteins expressed 
during the asexual stage were investigated using an immuno-
proteomics profiling method [4]. Difficulty expressing Pfs230 
and Pfs48/45 has been an obstacle to understand these anti-
gens [9,14,26]. Previous data on Pf92 showed that it localized 
to the merozoite surface and central parts of erythrocyte bind-
ing sites [16,17]. However, the orthologue of Pf92 in P. vivax, 
DIC α-PvMSP1-19 α-Pv92 DAPI Merge
Fig. 3. Localization of Pv92 at the mature schizont stage. The parasites were co-labeled with antisera against Pv92 (red color), PvM-
SP1-19 (merozoite surface marker, green color), and DAPI (nuclei marker, blue color).
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Fig. 4. Humoral responses to Pv92 as determined by protein ar-
rays. Pv92 was reacted with the sera of vivax malaria patients 
(positive) or healthy individuals (negative) from Korea. The preva-
lence of anti-Pv92 IgG differed significantly between vivax patients 
and healthy individuals (P<0.0001). P-value was calculated using 
Mann-Whitney U tests. Bar indicates the mean plus SD.
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Pv92, remains uncharacterized. Thus, herein, the N-terminal 
of Pv92 was expressed and purified using an E. coli protein ex-
pression system, and then characterized. The expressed Pv92 
protein reacted with the pooled vivax patient sera, indicating 
that it was immunogenic and may be important role in mero-
zoite attachment and invasion of erythrocytes. To evaluate the 
antigenicity of Pv92 using individual vivax patient serum, a 
protein array was carried out using the sera of 32 patients and 
20 healthy individuals. Among them, 65% of the serum of 
vivax patients (Table 1) showed seropositivity, which is lower 
than that of PvMSP1-19 [18]. In P. falciparum, Pf92 is localized 
on the merozoite surface at the late schizont stage and is also 
present at the ring stage [16]. In a previous report of proteins 
of the s48/45 family in P. vivax, the antigenicity of Pv41 was 
similar to that of the merozoite surface protein Pv92 [18], 
while another s48/45 family protein, Pv12, which is a rhoptry 
protein, showed lower antigenicity than Pv92 [19], indicating 
that Pv92 is a moderate antigenic protein among s48/45 fami-
ly in P. vivax. To determine the localization of Pv92 in para-
sites, IFA was performed with rabbit anti-PvMSP1-19 as a posi-
tive control and it is localized on the merozoite surface on the 
schizont stage parasites, indicating that Pv92 may play an im-
portant role for attachment and invasion of erythrocyte in 
blood stage.
In a recent study, Pv12 and Pv42, the s48/45 family protein, 
were produced high IgG antibody responses in naturally ac-
quired immune response analysis of filed isolates [27]. How-
ever, Pv92 was observed the lowest IgG antibody responses in 
naturally P. vivax-exposed individuals among 34 merozoite 
proteins of P. vivax [27]. We could not compared with our 
study and other merozite antigens because expression meth-
ods (bacterial or eukaryotic expression), serum samples (pa-
tients, age, etc.) and screening methods (ELISA or protein ar-
ray) with diverse sensitivities were affected on candidate selec-
tion. Although the technical difficulties such as long-term cul-
ture system of P. vivax, it will be required to analyze function of 
Pv92 during erythrocyte invasion of blood stage parasites and 
determine the potential of these proteins as serological marker.
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